A multimechanistic antibody targeting the receptor binding site potently cross-protects against influenza B viruses - PubMed (original) (raw)
. 2017 Oct 18;9(412):eaam5752.
doi: 10.1126/scitranslmed.aam5752.
Junyu Chen 1, Rui Li 1, Mengya Zhang 1, Guosong Wang 1, Svetlana Stegalkina 2, Limin Zhang 1, Jing Chen 1, Jianli Cao 1, Xingjian Bi 1, Stephen F Anderson 2, Timothy Alefantis 2, Minwei Zhang 3, Xiaoyang Cai 3, Kunyu Yang 4, Qingbing Zheng 1, Mujing Fang 1, Hai Yu 1, Wenxin Luo 1, Zizheng Zheng 1, Quan Yuan 1, Jun Zhang 1, James Wai-Kuo Shih 1, Harry Kleanthous 2, Honglin Chen 1 5, Yixin Chen 6, Ningshao Xia 6
Affiliations
- PMID: 29046433
- DOI: 10.1126/scitranslmed.aam5752
A multimechanistic antibody targeting the receptor binding site potently cross-protects against influenza B viruses
Chenguang Shen et al. Sci Transl Med. 2017.
Abstract
Influenza B virus causes considerable disease burden worldwide annually, highlighting the limitations of current influenza vaccines and antiviral drugs. In recent years, broadly neutralizing antibodies (bnAbs) against hemagglutinin (HA) have emerged as a new approach for combating influenza. We describe the generation and characterization of a chimeric monoclonal antibody, C12G6, that cross-neutralizes representative viruses spanning the 76 years of influenza B antigenic evolution since 1940, including viruses belonging to the Yamagata, Victoria, and earlier lineages. Notably, C12G6 exhibits broad cross-lineage hemagglutination inhibition activity against influenza B viruses and has higher potency and breadth of neutralization when compared to four previously reported influenza B bnAbs. In vivo, C12G6 confers stronger cross-protection against Yamagata and Victoria lineages of influenza B viruses in mice and ferrets than other bnAbs or the anti-influenza drug oseltamivir and has an additive antiviral effect when administered in combination with oseltamivir. Epitope mapping indicated that C12G6 targets a conserved epitope that overlaps with the receptor binding site in the HA region of influenza B virus, indicating why it neutralizes virus so potently. Mechanistic analyses revealed that C12G6 inhibits influenza B viruses via multiple mechanisms, including preventing viral entry, egress, and HA-mediated membrane fusion and triggering antibody-dependent cell-mediated cytotoxicity and complement-dependent cytotoxicity responses. C12G6 is therefore a promising candidate for the development of prophylactics or therapeutics against influenza B infection and may inform the design of a truly universal influenza vaccine.
Copyright © 2017 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works.
Comment in
- Influenza: A broadly protective antibody.
Palese P. Palese P. Nature. 2017 Nov 15;551(7680):310-311. doi: 10.1038/551310a. Nature. 2017. PMID: 29144466 No abstract available.
Similar articles
- An IgM antibody targeting the receptor binding site of influenza B blocks viral infection with great breadth and potency.
Shen C, Zhang M, Chen Y, Zhang L, Wang G, Chen J, Chen S, Li Z, Wei F, Chen J, Yang K, Guo S, Wang Y, Zheng Q, Yu H, Luo W, Zhang J, Chen H, Chen Y, Xia N. Shen C, et al. Theranostics. 2019 Jan 1;9(1):210-231. doi: 10.7150/thno.28434. eCollection 2019. Theranostics. 2019. PMID: 30662563 Free PMC article. - Broadly Cross-Reactive, Nonneutralizing Antibodies against Influenza B Virus Hemagglutinin Demonstrate Effector Function-Dependent Protection against Lethal Viral Challenge in Mice.
Asthagiri Arunkumar G, Ioannou A, Wohlbold TJ, Meade P, Aslam S, Amanat F, Ayllon J, García-Sastre A, Krammer F. Asthagiri Arunkumar G, et al. J Virol. 2019 Mar 5;93(6):e01696-18. doi: 10.1128/JVI.01696-18. Print 2019 Mar 15. J Virol. 2019. PMID: 30626682 Free PMC article. - Mapping of a Novel H3-Specific Broadly Neutralizing Monoclonal Antibody Targeting the Hemagglutinin Globular Head Isolated from an Elite Influenza Virus-Immunized Donor Exhibiting Serological Breadth.
Qiu Y, Stegalkina S, Zhang J, Boudanova E, Park A, Zhou Y, Prabakaran P, Pougatcheva S, Ustyugova IV, Vogel TU, Mundle ST, Oomen R, Delagrave S, Ross TM, Kleanthous H, Qiu H. Qiu Y, et al. J Virol. 2020 Feb 28;94(6):e01035-19. doi: 10.1128/JVI.01035-19. Print 2020 Feb 28. J Virol. 2020. PMID: 31826999 Free PMC article. - Broadly neutralizing antibodies to combat influenza virus infection.
Sun X, Ma H, Wang X, Bao Z, Tang S, Yi C, Sun B. Sun X, et al. Antiviral Res. 2024 Jan;221:105785. doi: 10.1016/j.antiviral.2023.105785. Epub 2023 Dec 23. Antiviral Res. 2024. PMID: 38145757 Review. - A Perspective on the Structural and Functional Constraints for Immune Evasion: Insights from Influenza Virus.
Wu NC, Wilson IA. Wu NC, et al. J Mol Biol. 2017 Aug 18;429(17):2694-2709. doi: 10.1016/j.jmb.2017.06.015. Epub 2017 Jun 23. J Mol Biol. 2017. PMID: 28648617 Free PMC article. Review.
Cited by
- Identification of mpox M1R and B6R monoclonal and bispecific antibodies that efficiently neutralize authentic mpox virus.
Ren Z, Li M, Chen J, Gong X, Song S, Li D, Yang M, Yu J, Asghar S, Cui Y, Niu S, Liao Z, Jiang Y, Liu J, Li Y, Zhang B, Zhao W, Peng J, Yang Y, Shen C. Ren Z, et al. Emerg Microbes Infect. 2024 Dec;13(1):2401931. doi: 10.1080/22221751.2024.2401931. Epub 2024 Sep 19. Emerg Microbes Infect. 2024. PMID: 39233480 Free PMC article. - Immune imprinting in early life shapes cross-reactivity to influenza B virus haemagglutinin.
Edler P, Schwab LSU, Aban M, Wille M, Spirason N, Deng YM, Carlock MA, Ross TM, Juno JA, Rockman S, Wheatley AK, Kent SJ, Barr IG, Price DJ, Koutsakos M. Edler P, et al. Nat Microbiol. 2024 Aug;9(8):2073-2083. doi: 10.1038/s41564-024-01732-8. Epub 2024 Jun 18. Nat Microbiol. 2024. PMID: 38890491 - A Chymotrypsin-Dependent Live-Attenuated Influenza Vaccine Provides Protective Immunity against Homologous and Heterologous Viruses.
He P, Gui M, Chen T, Zeng Y, Chen C, Lu Z, Xia N, Wang G, Chen Y. He P, et al. Vaccines (Basel). 2024 May 8;12(5):512. doi: 10.3390/vaccines12050512. Vaccines (Basel). 2024. PMID: 38793763 Free PMC article. - Natural History of Influenza B Virus-Current Knowledge on Treatment, Resistance and Therapeutic Options.
Din GU, Hasham K, Amjad MN, Hu Y. Din GU, et al. Curr Issues Mol Biol. 2023 Dec 26;46(1):183-199. doi: 10.3390/cimb46010014. Curr Issues Mol Biol. 2023. PMID: 38248316 Free PMC article. Review. - Three neutralizing mAbs induced by MPXV A29L protein recognizing different epitopes act synergistically against orthopoxvirus.
Li M, Ren Z, Wang Y, Jiang Y, Yang M, Li D, Chen J, Liang Z, Lin Y, Zeng Z, Xu R, Wang Y, Zhu L, Xiao W, Wu Q, Zhang B, Wan C, Yang Y, Wu B, Peng J, Zhao W, Shen C. Li M, et al. Emerg Microbes Infect. 2023 Dec;12(2):2223669. doi: 10.1080/22221751.2023.2223669. Emerg Microbes Infect. 2023. PMID: 37288876 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources